-

Bristol Myers Squibb to Participate in the TD Cowen 44th Annual Health Care Conference

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in the TD Cowen 44th Annual Health Care Conference in Boston, Massachusetts, on Monday, March 4, 2024. Roland Chen, M.D., senior vice president, Immunology, Cardiovascular & Neuroscience development, will answer questions about the company during a fireside chat at 9:50 a.m. ET.

Investors and the general public are invited to listen to a live webcast of the session here. An archived edition of the session will be available following its conclusion.

About Bristol Myers Squibb Company

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook, and Instagram.

corporatefinancial-news

Bristol Myers Squibb

NYSE:BMY

Release Summary
Bristol Myers Squibb to Participate in the TD Cowen 44th Annual Health Care Conference
Release Versions

More News From Bristol Myers Squibb

Bristol Myers Squibb Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans...

Bristol Myers Squibb to Report Results for Fourth Quarter 2025 on February 5, 2026

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Report Results for Fourth Quarter 2025 on February 5, 2026...

U.S. Food and Drug Administration (FDA) Grants Priority Review to Bristol Myers Squibb's Application for Opdivo® (nivolumab) Plus Chemotherapy Combination for Classical Hodgkin Lymphoma

PRINCETON, N.J.--(BUSINESS WIRE)--US FDA Grants Priority Review to Bristol Myers Squibb's Application for Opdivo (nivolumab) Plus Chemotherapy Combination for Classic Hodgkin Lymphoma...
Back to Newsroom